22 September 2015 | News | By BioSpectrum Bureau
Novo Nordisk to invest $78 mn in Iran
With construction of the new facility, Novo Nordisk will create 160 jobs
Singapore: Global pharmaceutical company, Novo Nordisk, plans to build a manufacturing plant for FlexPen prefilled devices in Iran.
The project is expected to last five years and represents a Novo Nordisk investment of approximately USD 78 million (70 million euros). The production will function in compliance with Good Manufacturing Practices (GMP).
"We are happy to commit to this manufacturing facility in Iran. It signals our long-term commitment to Iran, a country where close to five million people have diabetes according to the International Diabetes Federation. This investment will ensure availability of our modern insulins and will bring us a step closer to the people who rely on our products", said Mr Ole Moelskov Bech, corporate vice president, Novo Nordisk Business Area Near East.
With construction of the new facility, Novo Nordisk will create 160 jobs; Novo Nordisk already employs around 130 people in Iran.